Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1741396 | 1.00 | FLT4 (0.49) | FLT4KDRHPGDCCNB2CDK1 | |
| Hydrochloric Acid SCHEMBL1741379 | 0.88 | FLT4 (0.51) | FLT4KDR | |
| SCHEMBL1741183 | 0.87 | FLT4 (0.52) | FLT4KDR | |
| Hydrochloric Acid SCHEMBL1741160 | 0.84 | ADORA2A (0.54) | — | |
| SCHEMBL1740810 | 0.84 | ADORA2A (0.54) | — | |
| SCHEMBL11899822 | 0.81 | FLT4 (0.41) | FLT4KDRHPGDCCNB2CDK1 | |
| SCHEMBL11899641 | 0.81 | FLT4 (0.41) | FLT4KDRHPGDCCNB2CDK1 | |
| SCHEMBL11900999 | 0.80 | PDE2A (0.55) | CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1742886 | 0.80 | PDE2A (0.55) | CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL11899223 | 0.77 | FLT4 (0.41) | FLT4KDRHPGDTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202287-A1 | Stem Cell Culture Methods | ITI SCOTLAND LIMITED (GB) | 2012-08-09 | — | — | US | disclosed |
| EP-2389436-A2 | STEM CELL CULTURE METHODS | ITI Scotland Limited (GB) | 2011-11-30 | — | — | EP | disclosed |
| US-20110257911-A1 | SYSTEMS AND METHODS FOR DETECTING CHANGES IN ENERGY USAGE IN A BUILDING | JOHNSON CONTROLS TECHNOLOGY COMPANY | 2011-10-20 | — | — | US | disclosed |
| WO-2010084300-A2 | STEM CELL CULTURE METHODS | ITI SCOTLAND LIMITED (GB) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202287-A1 | Stem Cell Culture Methods | KIT, SOX18, MCL1 | FLT4 3150/4885KDR 3274/4885HPGD 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.